Vyndamax: how much TTR stabilization does tafamidis achieve at the approved dose?
Note: The ≥96% figure is an in vitro measurement in plasma at dose-relevant tafamidis concentrations (the study evaluated 1 to 30 μM; the page gives a mean peak plasma concentration of about 28 μM for tafamidis meglumine 80 mg once daily, VYNDAQEL). The 92% figure is derived from a model-based analysis, as the fourth passage states.